Literature DB >> 21365683

Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.

Eva Darian1, Olgun Guvench, Bing Yu, Cheng-Kui Qu, Alexander D MacKerell.   

Abstract

The SHP2 phosphatase plays a central role in a number of signaling pathways were it dephosphorylates various substrate proteins. Regulation of SHP2 activity is, in part, achieved by an intramolecular interaction between the PTP domain of the protein, which contains the catalytic site, and the N-SH2 domain leading to a "closed" protein conformation and autoinhibition. Accordingly, "opening" of the N-SH2 and PTP domains is required for the protein to become active. Binding of phosphopeptides to the N-SH2 domain is known to induce the opening event, while a number of gain-of-function (GOF) mutants, implicated in Noonan's Syndrome and childhood leukemias, are thought to facilitate opening. In the present study, a combination of computational and experimental methods are used to investigate the structural mechanism of opening of SHP2 and the impact of three GOF mutants, D61G, E76K, and N308D, on the opening mechanism. Calculated free energies of opening indicate that opening must be facilitated by effector molecules, possibly the protein substrates themselves, as the calculated free energies preclude spontaneous opening. Simulations of both wild type (WT) SHP2 and GOF mutants in the closed state indicate GOF activity to involve increased solvent exposure of selected residues, most notably Arg362, which in turn may enhance interactions of SHP2 with its substrate proteins and thereby aid opening. In addition, GOF mutations cause structural changes in the phosphopeptide-binding region of the N-SH2 domain leading to conformations that mimic the bound state. Such conformational changes are suggested to enhance binding of phosphopeptides and/or decrease interactions between the PTP and N-SH2 domains thereby facilitating opening. Experimental assays of the impact of effector molecules on SHP2 phosphatase activity against both small molecule and peptide substrates support the hypothesized mechanism of GOF mutant action. The present calculations also suggest a role for the C-SH2 domain of SHP2 in stabilizing the overall conformation of the protein in the open state, thereby aiding conformational switching between the open active and closed inactive states.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21365683      PMCID: PMC3076527          DOI: 10.1002/prot.22984

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  39 in total

1.  The penultimate rotamer library.

Authors:  S C Lovell; J M Word; J S Richardson; D C Richardson
Journal:  Proteins       Date:  2000-08-15

Review 2.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.

Authors:  Benjamin G Neel; Haihua Gu; Lily Pao
Journal:  Trends Biochem Sci       Date:  2003-06       Impact factor: 13.807

Review 3.  CHARMM: the biomolecular simulation program.

Authors:  B R Brooks; C L Brooks; A D Mackerell; L Nilsson; R J Petrella; B Roux; Y Won; G Archontis; C Bartels; S Boresch; A Caflisch; L Caves; Q Cui; A R Dinner; M Feig; S Fischer; J Gao; M Hodoscek; W Im; K Kuczera; T Lazaridis; J Ma; V Ovchinnikov; E Paci; R W Pastor; C B Post; J Z Pu; M Schaefer; B Tidor; R M Venable; H L Woodcock; X Wu; W Yang; D M York; M Karplus
Journal:  J Comput Chem       Date:  2009-07-30       Impact factor: 3.376

Review 4.  Protein tyrosine phosphatases in the JAK/STAT pathway.

Authors:  Dan Xu; Cheng-Kui Qu
Journal:  Front Biosci       Date:  2008-05-01

Review 5.  Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2.

Authors:  D Barford; B G Neel
Journal:  Structure       Date:  1998-03-15       Impact factor: 5.006

6.  Purification and characterization of PTP2C, a widely distributed protein tyrosine phosphatase containing two SH2 domains.

Authors:  Z Zhao; R Larocque; W T Ho; E H Fischer; S H Shen
Journal:  J Biol Chem       Date:  1994-03-25       Impact factor: 5.157

7.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.

Authors:  Marco Tartaglia; Charlotte M Niemeyer; Alessandra Fragale; Xiaoling Song; Jochen Buechner; Andreas Jung; Karel Hählen; Henrik Hasle; Jonathan D Licht; Bruce D Gelb
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

8.  Activation of the SH2-containing protein tyrosine phosphatase, SH-PTP2, by phosphotyrosine-containing peptides derived from insulin receptor substrate-1.

Authors:  S Sugimoto; T J Wandless; S E Shoelson; B G Neel; C T Walsh
Journal:  J Biol Chem       Date:  1994-05-06       Impact factor: 5.157

9.  Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.

Authors:  Marco Tartaglia; Simone Martinelli; Giovanni Cazzaniga; Viviana Cordeddu; Ivano Iavarone; Monica Spinelli; Chiara Palmi; Claudio Carta; Andrea Pession; Maurizio Aricò; Giuseppe Masera; Giuseppe Basso; Mariella Sorcini; Bruce D Gelb; Andrea Biondi
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

10.  Tyr66 acts as a conformational switch in the closed-to-open transition of the SHP-2 N-SH2-domain phosphotyrosine-peptide binding cleft.

Authors:  Olgun Guvench; Cheng-Kui Qu; Alexander D MacKerell
Journal:  BMC Struct Biol       Date:  2007-03-22
View more
  16 in total

Review 1.  PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots?

Authors:  Jessica Lauriol; Maria I Kontaridis
Journal:  Trends Cardiovasc Med       Date:  2011-05       Impact factor: 6.677

2.  Targeted Degradation of the Oncogenic Phosphatase SHP2.

Authors:  Vidyasiri Vemulapalli; Katherine A Donovan; Tom C M Seegar; Julia M Rogers; Munhyung Bae; Ryan J Lumpkin; Ruili Cao; Matthew T Henke; Soumya S Ray; Eric S Fischer; Gregory D Cuny; Stephen C Blacklow
Journal:  Biochemistry       Date:  2021-08-19       Impact factor: 3.162

3.  Structural and Functional Consequences of Three Cancer-Associated Mutations of the Oncogenic Phosphatase SHP2.

Authors:  Jonathan R LaRochelle; Michelle Fodor; Xiang Xu; Izabela Durzynska; Lixin Fan; Travis Stams; Ho Man Chan; Matthew J LaMarche; Rajiv Chopra; Ping Wang; Pascal D Fortin; Michael G Acker; Stephen C Blacklow
Journal:  Biochemistry       Date:  2016-04-11       Impact factor: 3.162

4.  Antagonism between binding site affinity and conformational dynamics tunes alternative cis-interactions within Shp2.

Authors:  Jie Sun; Shaoying Lu; Mingxing Ouyang; Li-Jung Lin; Yue Zhuo; Bo Liu; Shu Chien; Benjamin G Neel; Yingxiao Wang
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

5.  Phosphoproteomics-mediated identification of Fer kinase as a target of mutant Shp2 in Noonan and LEOPARD syndrome.

Authors:  Jeroen Paardekooper Overman; Christian Preisinger; Karin Prummel; Monica Bonetti; Piero Giansanti; Albert Heck; Jeroen den Hertog
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

6.  Shp2-Mitogen-Activated Protein Kinase Signaling Drives Proliferation during Zebrafish Embryo Caudal Fin Fold Regeneration.

Authors:  Alexander James Hale; Jeroen den Hertog
Journal:  Mol Cell Biol       Date:  2018-01-29       Impact factor: 4.272

7.  Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798.

Authors:  Xuemei Yang; Chunlan Tang; Hu Luo; Haijing Wang; Xiangdong Zhou
Journal:  Oncotarget       Date:  2017-04-04

8.  Aberrant neuronal activity-induced signaling and gene expression in a mouse model of RASopathy.

Authors:  Franziska Altmüller; Santosh Pothula; Anil Annamneedi; Saeideh Nakhaei-Rad; Carolina Montenegro-Venegas; Eneko Pina-Fernández; Claudia Marini; Monica Santos; Denny Schanze; Dirk Montag; Mohammad R Ahmadian; Oliver Stork; Martin Zenker; Anna Fejtova
Journal:  PLoS Genet       Date:  2017-03-27       Impact factor: 5.917

9.  Exploring the dynamic mechanism of allosteric drug SHP099 inhibiting SHP2E69K.

Authors:  Xin-Hua Lu; Wei-Ya Li; Shan Du; Li-Peng Li; Yang-Chun Ma; Liang Zhou; Jing-Wei Wu; Ying Ma; Run-Ling Wang
Journal:  Mol Divers       Date:  2021-01-03       Impact factor: 2.943

10.  ROCKs cause SHP-wrecks and broken hearts.

Authors:  Panna Tandon; Frank L Conlon; Joan M Taylor
Journal:  Small GTPases       Date:  2012-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.